Acquired Haemophilia A: A Review of What We Know

References

• Huth-Kühne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired haemophilia A. Haematologica. 2009;94(4):566–575. doi:10.3324/haematol.2008.001743
   PubMed Web of Science ®Google Scholar
• Kessler CM, Ma AD, Al-Mondhiry HA, Gut RZ, Cooper DL. Assessment of acquired haemophilia patient demographics in the United States: the hemostasis and thrombosis research society registry. Blood Coagul Fibrinolysis. 2016;27:761–769. doi:10.1097/MBC.0000000000000582
   PubMed Web of Science ®Google Scholar
• Koebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired haemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622–631. doi:10.1111/j.1538-7836.2012.04654.x
   PubMed Web of Science ®Google Scholar
• Tiede A, Klamrooth R, Scharf RE, et al. Pronostic factors for remission and survival in acquired haemophilia A (AHA): results from the GTH-AH 01/study. Blood. 2015;1257:1091–1109. doi:10.1182/blood-2014-07-587089
   Web of Science ®Google Scholar
• Mingot-Castellano ME, Pardos Gea J, Haya S, et al. Management of acquired haemophilia A: results from the Spanish registry. Blood Adv. 2021;5:3821–3829. doi:10.1182/bloodadvances.2021004626
   PubMed Web of Science ®Google Scholar
• Schep SJ, van Dijk WEM, Beckers EAM, et al. Treatment of acquired haemophilia A: results from 27 years Dutch cohort study. Am J Hematol. 2021;96:51–59. doi:10.1002/ajh.26009
   PubMed Web of Science ®Google Scholar
• Borg JY, Guillet B, Le Cam-Duchez V, Goudemand J, Lévesque H; SACHA Study Group. Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l’Hémophilie Acquise) registry. Haemophilia. 2013;19:564–570. doi:10.1111/hae.12138
   PubMed Web of Science ®Google Scholar
• Sun B, Xue F, Feng Y, et al. Outcome of CARE: a 6-year national registry of acquired haemophilia A in China. Br J Haematol. 2019;187(5):653–665. doi:10.1111/bjh.16128
   PubMed Web of Science ®Google Scholar
• Delgado J, Jiménez-Yuste V, Hernando-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121:21–35.
   PubMed Web of Science ®Google Scholar
• Collins PW, Hirsch S, Baglin TP, et al. Acquired haemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom haemophilia centre doctors’ organisation. Blood. 2007;109(5):1870–1877. doi:10.1182/blood-2006-06-029850
   PubMed Web of Science ®Google Scholar
• Tiede A, Wahler S. The rising incidence of acquired haemophilia A in Germany. Haemophilia. 2021;27(4):e466–e468. doi:10.1111/hae.14149
   PubMed Web of Science ®Google Scholar
• Franchini M, Zaffanello M, Lippi G. Acquired haemophilia in pediatrics: a systematic review. Pediatr Blood Cancer. 2010;55(4):606–611. doi:10.1002/pbc.22657
   PubMed Web of Science ®Google Scholar
• Charlebois J, Rivard GE, St-Louis J. Management of acquired haemophilia A: review of current evidence. Transfus Apher Sci. 2018;57(6):717–720. doi:10.1016/j.transci.2018.10.011
   PubMed Web of Science ®Google Scholar
• Pishko A, Doshi BS. Acquired Haemophilia A: current guidance and experience from clinical practice. J Blood Med. 2022;13:255–265. doi:10.2147/JBM.S284804
   PubMed Web of Science ®Google Scholar
• Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired haemophilia A. Haematologica. 2020;105(7):1791–1801. doi:10.3324/haematol.2019.230771
   PubMed Web of Science ®Google Scholar
• Mingot-Castellano ME, Núñez R, Rodríguez-Martorell FJ. Acquired haemophilia: epidemiology, clinical presentation, diagnosis and treatment. Med Clin. 2017;148(7):314–322. doi:10.1016/j.medcli.2016.11.030
   PubMed Web of Science ®Google Scholar
• Guerrero-Camacho R, Alvarez-Román MT, Butta-Coll N, et al. Acquired Haemophilia A: a 15-year single-centre experience of demography, clinical features and outcome. J Clin Med. 2022;11:2721.
   PubMed Web of Science ®Google Scholar
• Portuguese AJ, Sunga C, Kruse-Jarres R, Gernsheimer T, Abkowitz J. Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination. Blood Adv. 2021;5(13):2794–2798. doi:10.1182/bloodadvances.2021004957
   PubMed Web of Science ®Google Scholar
• Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981;45(3):200–203. doi:10.1055/s-0038-1650169
   PubMed Web of Science ®Google Scholar
• Godreuil S, Navarro R, Quittet P, Landreau L, Schved JF, Biron-Andréani C. Acquired haemophilia in the elderly is a severe disease: report of five new cases. Haemophilia. 2001;7(4):428–432. doi:10.1046/j.1365-2516.2001.00531.x
   PubMed Web of Science ®Google Scholar
• Baudo F, de Cataldo F. Acquired haemophilia in the elderly. In: Balducci L, Ershler W, de Gaetano G, editors. Blood Disorders in the Elderly. Cambridge: Cambridge University Press; 2007:389–407.
   Google Scholar
• Kessler CM. Acquired factor VIII autoantibody inhibitors: current concepts and potential therapeutic strategies for the future. Haematologica. 2000;85:57–61.
   PubMedGoogle Scholar
• Napolitano M, Siragusa S, Mancuso S, Kessler CM. Acquired haemophilia in cancer: a systematic and critical literature review. Haemophilia. 2018;24(1):43–56. doi:10.1111/hae.13355
   PubMed Web of Science ®Google Scholar
• Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Cancer. 2001;91:1067–1074. doi:10.1002/1097-0142(20010315)91:6<1067::AID-CNCR1101>3.0.CO;2-4
   PubMed Web of Science ®Google Scholar
• Hauser I, Lechner K. Solid tumors and factor VIII antibodies. Thromb Haemost. 1999;82(3):1005–1007. doi:10.1055/s-0037-1614318
   PubMed Web of Science ®Google Scholar
• Sallah S, Singh P, Hanrahan LR. Antibodies against factor VIII in patients with solid tumors: successful treatment of cancer may suppress inhibitor formation. Haemostasis. 1998;28(5):244–249. doi:10.1159/000022438
   PubMedGoogle Scholar
• Sohngen D, Specker C, Bach D, et al. Acquired factor VIII inhibitors in nonhemophilic patients. Ann Hematol. 1997;74:89–93. doi:10.1007/s002770050263
   PubMed Web of Science ®Google Scholar
• Hultin MB. Acquired inhibitors in malignant and nonmalignant disease states. Am J Med. 1991;91(5A):9S–13S. doi:10.1016/S0002-9343(91)80141-8
   PubMed Web of Science ®Google Scholar
• Lionnet F, Pulik M, Genet P, Lucas G, Sollet JP. Acquired factor VIII inhibitor associated with a prostate cancer: simultaneous occurrence and healing. Thromb Haemost. 1995;73:327–328. doi:10.1055/s-0038-1653775
   PubMed Web of Science ®Google Scholar
• Lopez R, Mateo J, Cruz J, Lopez A, Urrutia F, Fontcuberta J. Presentation of an acquired factor VIII inhibitor with a muscular haematoma mimicking a deep venous thrombosis in a patient with breast cancer. Blood Coagul Fibrinolysis. 1995;6:680–682. doi:10.1097/00001721-199510000-00010
   PubMed Web of Science ®Google Scholar
• Neilson RF, Walker ID, Roberson M. Factor VIII inhibitor associated with hepatocellular carcinoma. Clin Lab Haematol. 1993;15:145–148. doi:10.1111/j.1365-2257.1993.tb00139.x
   PubMedGoogle Scholar
• Shurafa M, Raman S, Wollner I. Disappearance of factor VIII antibody after removal of primary colon adenocarcinoma. Am J Hematol. 1995;50:149–150. doi:10.1002/ajh.2830500218
   PubMed Web of Science ®Google Scholar
• Italian Association of Haemophilia Centres (AICE). Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Registry relevant to clinical practice. Int J Obstet Gynaecol. 2003;110:311–314. doi:10.1016/S1470-0328(03)01935-9
   Web of Science ®Google Scholar
• Kashyap R, Choudhry VP, Mahapatra M, Chumber S, Saxena R, Kaul HL. Postpartum acquired haemophilia: clinical recognition and management. Haemophilia. 2001;7:327–330. doi:10.1046/j.1365-2516.2001.00506.x
   PubMed Web of Science ®Google Scholar
• Tengborn L, Baudo F, Huth-Künhne A, et al. Pregnancy-associated acquired haemophilia: a results from the European Acquired Heamophilia registry (EAHCH2). BJOG. 2012;119:1529–1537. doi:10.1111/j.1471-0528.2012.03469.x
   PubMed Web of Science ®Google Scholar
• Solymoss S. Postpartum acquired factor VIII inhibitors: results of a survey. Am J Hematol. 1998;59(1):1–4. doi:10.1002/(SICI)1096-8652(199809)59:1<1::AID-AJH1>3.0.CO;2-T
   PubMed Web of Science ®Google Scholar
• Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol. 2006;81(10):768–773. doi:10.1002/ajh.20702
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Bosch LJ, Van Del Plas PM, et al. Factor VIII inhibitor postpartum. Scand J Haematol. 1978;20:97–107. doi:10.1111/j.1600-0609.1978.tb02434.x
   PubMedGoogle Scholar
• Michiels JJ. Acquired haemophilia A in women postpartum: clinical manifestations, diagnosis, and treatment. Clin Appl Thromb Hemost. 2000;6(2):82–86. doi:10.1177/107602960000600206
   PubMed Web of Science ®Google Scholar
• Hauser I, Schneider B, Lechner K. Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost. 1995;73(1):1–5. doi:10.1055/s-0038-1651666
   PubMed Web of Science ®Google Scholar
• Shobeiri SA, West EC, Kahn MJ, Nolan TE. Postpartum acquired haemophilia (factor VIII inhibitors): a case report and review of the literature. Obstet Gynecol Surv. 2000;55(12):729–737. doi:10.1097/00006254-200012000-00003
   PubMed Web of Science ®Google Scholar
• Dewarrat N, Gavillet M, Angelillo-Scherrer A, et al. Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: a systematic literature review. Haemophilia. 2021;27(2):199–210. doi:10.1111/hae.14233
   PubMed Web of Science ®Google Scholar
• Franchini M, Capra F, Nicolini N, et al. Drug-induced anti-factor VIII antibodies: a systematic review. Med Sci Monit. 2007;13(4):RA55–61.
   PubMed Web of Science ®Google Scholar
• André S, Meslier Y, Dimitrov J, et al. A Cellular viewpoint of anti-FVIII immune response in haemophilia A. Clinic Rev Allerg Immunol. 2009;37:105–113. doi:10.1007/s12016-009-8117-2
   PubMed Web of Science ®Google Scholar
• Reding MT, Wu H, Krampf M, et al. CD4+ T response to factor VIII in haemophilia A, acquired haemophilia and Healthy subjects. Thromb Haemost. 1999;82:509–515. doi:10.1055/s-0037-1615873
   PubMed Web of Science ®Google Scholar
• Reding MT, Lei S, Lei H, Green D, Gill J, Conti-Fine BM. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired haemophilia patients. ThrombHaemost. 2002;88:568–575.
   Google Scholar
• Wootla B, Desirazu N, Friboulet A, Uda T, Lacroix-Desmazes S, Kaveri S. Varied immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies. Clinic Rev Allerg Immunol. 2009;37:97–104. doi:10.1007/s12016-009-8116-3
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Zeitler H, Pavlova A. Genetic markers in acquired haemophilia. Haemophilia. 2010;16(Suppl3):41–45. doi:10.1111/j.1365-2516.2010.02259.x
   PubMed Web of Science ®Google Scholar
• Boggio LN, Green D. Acquired haemophilia. Rev ClinExpHematol. 2001;5(4):389–404.
   Google Scholar
• Lacroix-Desmazes S, Bayry J, Kaveri SV. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc Natl Acad Sci U S A. 2005;102:4109–4113. doi:10.1073/pnas.0500586102
   PubMed Web of Science ®Google Scholar
• Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood. 1987;69(5):1475–1480. doi:10.1182/blood.V69.5.1475.1475
   PubMed Web of Science ®Google Scholar
• Shapiro SS. The immunologic character of acquired inhibitors of antihemophilic globulin (factor 8) and the kinetics of their interaction with factor 8. J Clin Invest. 1967;46(2):147–156. doi:10.1172/JCI105517
   PubMed Web of Science ®Google Scholar
• Hoyer LW, Gawryl MS, de la Fuente B. Immunological characterization fo factor VIII inhibitors. In: Hoyer LW, editor. Factor VIII Inhibitors. New York: Liss; 1995:73–85.
   Google Scholar
• Pruthi RK, Nichols WL. Autoimmune factor VIII inhibitors. Curr Opin Hematol. 1999;6(5):314–322. doi:10.1097/00062752-199909000-00008
   PubMedGoogle Scholar
• Mingot-Castellano ME, Moret A, de Cos C, et al. Involvement of antifactor VIII autoantibodies specificity in the outcome of inhibitor eradication therapies in acquired haemophilia a patients. Blood Coagul Fibrinolysis. 2019;30(3):127–132. doi:10.1097/MBC.0000000000000804
   PubMed Web of Science ®Google Scholar
• Prescott R, Nakai H, Saemko EL, et al. The inhibitor antibody response is more complex in haemophilia A patients than in most nonhaemophiliacs with factor VIII antibodies. Blood. 1997;89:3663–3671. doi:10.1182/blood.V89.10.3663
   PubMedGoogle Scholar
• Gilles JGG, Jacquemin MG, Saint-Remy JMR. Factor VIII inhibitors. Thromb Haemost. 1997;78:641–646. doi:10.1055/s-0038-1657604
   PubMed Web of Science ®Google Scholar
• Nilsson IM, Berntorp E, Zettervall O, Dahlback B. Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in haemophilia A patients. Blood. 1990;75(2):378–383. doi:10.1182/blood.V75.2.378.378
   PubMed Web of Science ®Google Scholar
• Biggs R, Austen DE, Denson KW, Rizza CR, Borrett R. The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs. Br J Haematol. 1972a;23:125–135. doi:10.1111/j.1365-2141.1972.tb03467.x
   PubMed Web of Science ®Google Scholar
• Biggs R, Austen DE, Denson KW, Borrett R, Rizza CR. The mode of action of antibodies which destroy factor VIII. II Antibodies Which Give Complex Concentration Graphs. Br J Haematol. 1972b;23:135–155.
   Web of Science ®Google Scholar
• Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood. 1982;60(5):1103–1109. doi:10.1182/blood.V60.5.1103.1103
   PubMed Web of Science ®Google Scholar
• Rasmussen KL, Philips M, Tripodi A, Goetze JP. Unexpected, isolated activated partial thromboplastin time prolongation: a practical mini-review. Eur J Haematol. 2020;104(6):519–525. doi:10.1111/ejh.13394
   PubMed Web of Science ®Google Scholar
• Barbosa ACN, Montalvão SAL, Barbosa KGN, et al. Prolonged aPTT of unknown etiology: a systematic evaluation of causes and laboratory resource use in an outpatient hemostasis academic unit. Res Pract Thromb Haemost. 2019;3(4):749–757. doi:10.1002/rth2.12252
   PubMed Web of Science ®Google Scholar
• McGinnis E, Wong SKW, Smith TW. Evaluation of activated partial thromboplastin time coagulation waveform analysis for identification of patients with acquired factor VIII inhibitors. Int J Lab Hematol. 2020;42(4):411–417. doi:10.1111/ijlh.13211
   PubMed Web of Science ®Google Scholar
• Lossing TS, Kasper CK, Feinstein DI. Detection of factor VIII inhibitors with the partial thromboplastin time. Blood. 1977;49(5):793–797. doi:10.1182/blood.V49.5.793.793
   PubMed Web of Science ®Google Scholar
• Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired haemophilia A: limitations, consequences, and challenges. Semin Thromb Hemost. 2014;40(7):803–811. doi:10.1055/s-0034-1390004
   PubMed Web of Science ®Google Scholar
• Blanco AN, Cardozo MA, Candela M, Santarelli MT, Perez Bianco R, Lazzari MA. Anti-factor VIII inhibitors and lupus anticoagulants in haemophilia A patients. Thromb Haemost. 1997;77(4):656–659. doi:10.1055/s-0038-1656029
   PubMed Web of Science ®Google Scholar
• de Maistre E, Wahl D, Perret-Guillaume C, et al. A chromogenic assay allows reliable measurement of factor VIII levels in the presence of strong lupus anticoagulants. Thromb Haemost. 1998;79(1):237–238. doi:10.1055/s-0037-1614254
   PubMed Web of Science ®Google Scholar
• Rampersad AG, Boylan B, Miller CH, Shapiro A. Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients. Haemophilia. 2018;24(5):807–814. doi:10.1111/hae.13565
   PubMed Web of Science ®Google Scholar
• Chikasawa Y, Amano K, Miyashita R, et al. Discrimination between acquired haemophilia A and lupus anticoagulant using rotational thromboelastometry (ROTEM) [abstract]. Res Pract Thromb Haemost. 2020;4(Suppl 1):1.
   Google Scholar
• Hosoi H, Akagi Y, Mushino T, et al. Use of thromboelastography before the administration of haemostatic agents to safely taper recombinant activated factor VII in acquired haemophilia A: a report of three cases. Thromb J. 2022;20(1):28. doi:10.1186/s12959-022-00387-x
   PubMed Web of Science ®Google Scholar
• Jacobs JW, Gisriel SD, Iyer K, Rinder HM. Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient. J Thromb Thrombolysis. 2022;53(4):945–949. doi:10.1007/s11239-021-02591-4
   PubMed Web of Science ®Google Scholar
• Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood. 2008;112(2):250–255. doi:10.1182/blood-2008-03-143586
   PubMed Web of Science ®Google Scholar
• Miller CH. Laboratory testing for factor VIII and IX inhibitors in haemophilia: a review. Haemophilia. 2018;24(2):186–197. doi:10.1111/hae.13424
   PubMed Web of Science ®Google Scholar
• Kasper CK, Beetens JR, Van de Wiele R, Höller M, De Clerck F. Laboratory tests for factor VIII inhibitors, their variation, significance and interpretation. Blood Coagul Fibrinolysis. 1991;2(Suppl 1):7–10. doi:10.1097/00001721-199102000-00002
   PubMed Web of Science ®Google Scholar
• Kasper CK. Measurement of factor VIII inhibitors. Prog Clin Biol Res. 1984;150:87–98.
   PubMedGoogle Scholar
• Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73(2):247–251. doi:10.1055/s-0038-1653759
   PubMed Web of Science ®Google Scholar
• Boylan B, Miller CH. Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels. Haemophilia. 2018;24(3):487–491. doi:10.1111/hae.13435
   PubMed Web of Science ®Google Scholar
• Zhang J, Mu R, Chen J, Song J. Effect of different incubation times on the detection of factor VIII inhibitor in acquired haemophilia A. Clin Chem Lab Med. 2022;60(8):e195–e197. doi:10.1515/cclm-2022-0046
   PubMed Web of Science ®Google Scholar
• Holstein K, Liu X, Smith A, et al. Bleeding and response to haemostatic therapy in acquired haemophilia A: results from the GTH-AH 01/2010 study. Blood. 2020;136(3):279–287. doi:10.1182/blood.2019003639
   PubMed Web of Science ®Google Scholar
• Pardos-Gea J, Fernández-Díaz N, Parra R, Cortina V, Altisent C. Diagnostic delay in acquired haemophilia: analysis of causes and consequences in a 20-year Spanish cohort. Haemophilia. 2018;24(3):e163–e166. doi:10.1111/hae.13499
   PubMed Web of Science ®Google Scholar
• Kruse-Jarres R, Kempton CL, Baudo F, et al. Acquired haemophilia A: updated review of evidence and treatment guidance. Am J Hematol. 2017;92(7):695–705. doi:10.1002/ajh.24777
   PubMed Web of Science ®Google Scholar
• Tiede A, Giangrande P, Teitel J, et al. Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: a global expert consensus statement. Haemophilia. 2019;25(6):969–978. doi:10.1111/hae.13844
   PubMed Web of Science ®Google Scholar
• María Teresa Álvarez Roman, María Eva Mingot Castellano. Recomendaciones para el diagnostico y tratamiento de la hemofilia adquirida. Barcelona: Editorial Ambos Marketing Service, S.L; 2017:895. ISBN: 978-84-9459-45-2-6.
   Google Scholar
• Tiede A, Hofbauer CJ, Werwitzke S, et al. Anti-factor VIII IgA as a potential marker of poor prognosis in acquired haemophilia A: results from the GTH-AH 01/2010 study. Blood. 2016;127(19):2289–2297. doi:10.1182/blood-2015-09-672774
   PubMed Web of Science ®Google Scholar
• Ries M, Wolfel D, Maier-Brandt B. Severe intracranial hemorrhage in a new born infant with transplacental transfer of an acquired factor VIII inhibitor. J Pediatr. 1995;127:649–665. doi:10.1016/S0022-3476(95)70132-X
   PubMed Web of Science ®Google Scholar
• Vicente V, Alberca I, González R, Alegre A. Normal pregnancy in a patient with a postpartum factor VIII inhibitor. Am J Hematol. 1987;24:107–109. doi:10.1002/ajh.2830240114
   PubMed Web of Science ®Google Scholar
• Frick PG. Haemophilia like disease following pregnancy. Blood. 1953;8:598–599. doi:10.1182/blood.V8.7.598.598
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of haemophilia panelists and co-authors. WFH guidelines for the management of haemophilia. Haemophilia. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics of Novoseven. Available from: https://www.ema.europa.eu/en/documents/product-information/novoseven-epar-product-information_en.pdf. Accessed August 13, 2022.
   Google Scholar
• Summary of product characteristics of FEIBA. Available from: https://www.medicines.org.uk/emc/product/9192/smpc/print. Accessed August 13, 2022.
   Google Scholar
• Summary of product characteristics of Obizur. Available from: https://www.ema.europa.eu/en/documents/product-information/obizur-epar-product-information_en.pdf. Accessed August 13, 2022.
   Google Scholar
• Baudo F, Collins P, Huth-Kuhne A, et al. Management of bleeding in acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood. 2012;120(1):39–46. doi:10.1182/blood-2012-02-408930
   PubMed Web of Science ®Google Scholar
• Mingot-Castellano ME, Álvarez-Román MT, López-Fernández MF, et al. Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors. Eur J Haematol. 2016;96(5):461–474. doi:10.1111/ejh.12730
   PubMed Web of Science ®Google Scholar
• Tiede A, Worster A. Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia. Ann Hematol. 2018;97(10):1889–1901. doi:10.1007/s00277-018-3372-z
   PubMed Web of Science ®Google Scholar
• Dunkley SM, Yang K. The use of combination FEIBA and rFVIIa bypassing therapy, with TEG profiling, in uncontrollable bleeding associated with acquired haemophilia A. Haemophilia. 2009;15:828–830. doi:10.1111/j.1365-2516.2008.01927.x
   PubMed Web of Science ®Google Scholar
• Hay CRM, Sharpe T, Dolan G; UKHCDO. Use of the UKHCDO Database for a postmarketing surveillance study of different doses of recombinant factor VIIa in haemophilia. Haemophilia. 2017;23(3):376–382. doi:10.1111/hae.13139
   PubMed Web of Science ®Google Scholar
• Amano K, Seita I, Higasa S, Sawada A, Kuwahara M, Shima M. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data. Haemophilia. 2017;23(1):50–58. doi:10.1111/hae.13033
   PubMed Web of Science ®Google Scholar
• Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015;21(2):162–170. doi:10.1111/hae.12627
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Cuker A, Hardesty B, Roberts JC, Sholzberg M. Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients. Haemophilia. 2017;23(1):25–32. doi:10.1111/hae.13040
   PubMed Web of Science ®Google Scholar
• Ellsworth P, Chen SL, Kasthuri RS, Key NS, Mooberry MJ, Ma AD. Recombinant porcine FVIII for bleed treatment in acquired haemophilia A: findings from a single-center, 18-patient cohort. Blood Adv. 2020;4(24):6240–6249. doi:10.1182/bloodadvances.2020002977
   PubMed Web of Science ®Google Scholar
• Türkantoz H, Konigs C, Knobl P, et al. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired haemophilia A: data from the GTH-AH 01/2010 Study. J Thromb Haemost. 2020;18(1):36–43. doi:10.1111/jth.14618
   PubMed Web of Science ®Google Scholar
• Fosbury E, Drebes A, Riddell A, Chowdary P. Review of recombinant anti-haemophilic porcine sequence factor VIII in adults with acquired haemophilia A. Ther Adv Hematol. 2017;8(9):263–272. doi:10.1177/2040620717720861
   PubMed Web of Science ®Google Scholar
• Holmstrom M, Tran HT, Holme PA. Combined treatment with aPCC (FEIBA(R)) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A–a two-centre experience. Haemophilia. 2012;18(4):544–549. doi:10.1111/j.1365-2516.2012.02748.x
   PubMed Web of Science ®Google Scholar
• Takedani H, Shima M, Horikoshi Y, et al. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan. Haemophilia. 2015;21(3):374–379. doi:10.1111/hae.12611
   PubMed Web of Science ®Google Scholar
• Zanon E, Pasca S, Siragusa S, et al.; FAIR Study Group. Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: data from the FAIR registry. Thromb Res. 174;2019:24–26. doi:10.1016/j.thromres.2018.12.006
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics hemlibra. Available from: https://www.ema.europa.eu/en/documents/product-information/hemlibra-eparproduct-information_en.pdf. Accessed August 13, 2022.
   Google Scholar
• Knoebl P, Sperr WR, Schellongowski P, et al. Emicizumab for the treatment of acquired haemophilia A: lessons learned from 4 very different cases. Blood. 2018;132(Suppl 1):2476. doi:10.1182/blood-2018-99-116973
   Web of Science ®Google Scholar
• Mohnle P, Pekrul I, Spannagl M, Sturm A, Singh D, Dechant C. Emicizumab in the treatment of acquired haemophilia: a case report. Transfus Med Hemother. 2019;46(2):121–123. doi:10.1159/000497287
   PubMed Web of Science ®Google Scholar
• Poston JN, Al-Banaa K, von Drygalski A, et al. Emicizumab for the treatment of acquired haemophilia A: a multicenter US case series. Blood. 2021;138:496. doi:10.1182/blood-2021-148040
   Web of Science ®Google Scholar
• Knoebl P, Thaler J, Jilma P, Quehenberger P, Gleixner K, Sperr WR. Emicizumab for the treatment of acquired haemophilia A. Blood. 2021;137(3):410–419. doi:10.1182/blood.2020006315
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/results?cond=Acquired+Haemophilia&term=Emicizumab&cntry=&state=&city=&dist=. Accessed August 13, 2022.
   Google Scholar
• Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired haemophilia A: results from the European Acquired haemophilia registry (EACH2). Blood. 2012;1201:47–55. doi:10.1182/blood-2012-02-409185
   Web of Science ®Google Scholar
• Coppola A, Franchini M, Tripodi A, et al. Acquired haemophilia A: Italian consensus recommendations on diagnosis, general management and treatment of bleeding. Blood Transfusion. 2022;20:245–262. doi:10.2450/2022.0238-21
   PubMed Web of Science ®Google Scholar
• Green D, Rademaker AW, Briet E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with Factor VIII autoantibodies. Thromb Hemost. 1993;705:753–757.
   Google Scholar
• Franchini M, Vaglio S, Marano G, et al. Acquired Haemophilia A: a review of recent data and new therapeutic options. Hematology. 2017;22:514–520. doi:10.1080/10245332.2017.1319115
   PubMed Web of Science ®Google Scholar
• Dolan G, Benson G, Bowyer A, et al. Principles of care for acquired haemophilia. Eur J Hematol. 2021;106:762–773. doi:10.1111/ejh.13592
   PubMed Web of Science ®Google Scholar
• Yao Q, Zhu X, Liu Y, et al. Low-dose rituximab in the treatment of acquired haemophilia. Hematology. 2014;19(8):483–486. doi:10.1179/1607845414Y.0000000152
   PubMed Web of Science ®Google Scholar
• Remmington T, Smith S. Rituximab for eradicating inhibitors in people with acquired haemophilia A. Cochrane Database Syst Rev. 2021;8(8):CD011907. doi:10.1002/14651858.CD011907.pub3
   PubMed Web of Science ®Google Scholar
• Lapalud P, Ali T, Cayzac C, et al. The IgG autoimmune response in postpartum acquired haemophilia A targets mainly the A1a1 domain of FVIII. J Thromb Haemost. 2012;10:1814–1822. doi:10.1111/j.1538-7836.2012.04850.x
   PubMed Web of Science ®Google Scholar
• Bitting RL, Bent S, Li Y, Kohlwes J. The prognosis and treatment of acquired haemophilia: a systematic review and meta-analysis. Blood Coagul Fibrinolysis. 2009;20:517–523. doi:10.1097/MBC.0b013e32832ca388
   PubMed Web of Science ®Google Scholar
• Malpica L, Moll S. Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases. Hematology Am Soc Hematol Educ Program. 2020;2020(1):319–327. doi:10.1182/hematology.2020000116
   PubMed Web of Science ®Google Scholar
• González-Macías J, Del Pino-Montes J, Olmos JM, Nogués X. Clinical practice guidelines for postmenopausal, glucocorticoid-induced and male osteoporosis. Spanish society for research on bone and mineral metabolism (3rd updated version 2014). Rev Clin Esp (Barc). 2015;215(9):515–526. doi:10.1016/j.rce.2015.08.003
   PubMed Web of Science ®Google Scholar
• Sabater-Lleal M, Huffman JE, de Vries PS, et al. Genome-wide association transethnic meta-analyses identifies novel associations regulating coagulation factor viii and von Willebrand factor plasma levels. Circulation. 2019;139(5):620–635. doi:10.1161/CIRCULATIONAHA.118.034532
   PubMed Web of Science ®Google Scholar